Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.77 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.43 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2564919 | 0.91 | MAP2K1 (0.75) | MAP2K1MAP2K2PRKCZIARS2CYP2C9 | |
| SCHEMBL2565148 | 0.90 | MAP2K1 (0.72) | MAP2K1MAP2K2PRKCZIARS2CYP2C9 | |
| SCHEMBL2563367 | 0.89 | MAP2K1 (0.73) | MAP2K1MAP2K2PRKCZIARS2CYP2C9 | |
| SCHEMBL2560400 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2CYP2C9KCNH2CYP2C19 | |
| SCHEMBL29519571 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2CYP2C9KCNH2CYP2C19 | |
| SCHEMBL2565266 | 0.84 | MAP2K1 (0.75) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL2565670 | 0.84 | MAP2K1 (0.75) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL2562837 | 0.84 | MAP2K1 (0.66) | MAP2K1MAP2K2PRKCZIARS2CYP2C9 | |
| SCHEMBL2567349 | 0.84 | MAP2K1 (0.66) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL2565074 | 0.83 | MAP2K1 (0.65) | MAP2K1MAP2K2PRKCZIARS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069354-B1 | Aza-benzofuranyl compounds and methods of use | GENENTECH INC (US) | 2011-11-02 | — | — | EP | claimed |
| EP-2069354-B1 | Aza-benzofuranyl compounds and methods of use | GENENTECH INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | MAP2K1 10/4885MAP2K2 3/4885PRKCZ 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.